Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERONA: EYP-1901 in Diabetic Macular Edema
NCT06099184Phase 2Completed
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vorolanib in diabetic macular edema (DME) (3 arms), sponsored by EyePoint Pharmaceuticals. Primary endpoint: Time to first supplemental aflibercept injection at 24 weeks. Started Jan 2024; status: completed.
02
Drugs
vorolanib
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06099184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099184.